Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers-Reference-Cited by-同舟云学术

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

Published:2021-06-19 Issue:9 Volume:10 Page:1044-1053
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Zhang Steven¹,Jin Shu¹,Griffin Celina¹,Feng Zhongling¹,Lin Jianchang¹,Venkatakrishnan Karthik¹²,Gupta Neeraj¹

Affiliation:

1. Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

2. EMD Serono, Inc. Billerica Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.967

Reference16 articles.

1. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

2. Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations;Vasconcelos PENS;JTO Clin Res Rep,2021

3. Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

4. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants;Investigational New Drugs;2024-05-24

2. Mobocertinib: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2024-03

3. A Perspective of the Amide Group Containing FDA Approved Anticancer Drugs from 2021–2022 (A Review);Russian Journal of Bioorganic Chemistry;2023-11

4. Hexafluoroisopropanol/trifluoromethanesulfonic acid assists the synthesis of 3-(2-chloropyrimidin-4-yl)-1H-indoles;Tetrahedron;2023-10

5. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects;Expert Opinion on Drug Metabolism & Toxicology;2023-09-02